Let me tell you, folks, we’ve got something huge here. We’re talking about a game-changer in the fight against tuberculosis (TB), especially for people living with HIV. It’s this incredible regimen, just once a week, called isoniazid and rifapentine for 3 months – let’s call it 3HP. It’s critical, absolutely critical for reducing the global TB burden. And guess what? We’ve proven that with the right approach, acceptance and completion rates can go through the roof!

We ran this fantastic trial in Kampala, Uganda, at a big urban HIV clinic. It was no small feat – 1,656 people living with HIV were randomly assigned to one of three groups. They either got this 3HP through directly observed therapy (DOT), self-administered therapy (SAT), or they could choose between the two. And let me tell you, the results were incredible.

Across the board, acceptance and completion exceeded our target of 80%. We’re talking 94% in the DOT group, 92% in the SAT group, and 93% in the choice group. And the best part? There was no significant difference between the groups. This means people love having options, and they’re just as likely to complete their treatment whether they’re being watched or doing it themselves. Only 14 people had to stop because of side effects – that’s less than 1%!

Now, I know what you’re thinking. This was just one clinic. But let me assure you, this is just the beginning. We’re going to take this model, and we’re going to roll it out everywhere. Because when you tailor your approach, when you give people choices, you get results. And these results? They’re huge.

So, let’s not waste any more time. It’s time to expand this approach and make a real difference in the fight against TB and HIV. We’ve got the proof, now let’s get to work!